Insider Trading activities of Cv Therapeutics Inc insiders.

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Cv Therapeutics Inc since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Cv Therapeutics Inc since year 2005. Table 2 shows the detailed insider transactions of Cv Therapeutics Inc since 2005. The reporting company's ticker symbol is CVTX. The reporting company's CIK number is 921506.
The total value of stock buying since 2005 is $61,080.
The total value of stock sales since 2005 is $14,026,759.
The total value of stock option exercises since 2005 is $25,196,819.


Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Cv Therapeutics Inc (CVTX).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2009-04 0 $0 620,204 $12,343,469 1,543,765 $21,386,422
2009-03 0 $0 0 $0 11,345 $225,538
2009-02 0 $0 1,500 $23,250 87,497 $1,363,202
2009-01 0 $0 1,500 $14,070 801 $7,473
2008-12 0 $0 1,002 $9,248 70,746 $635,395
2008-11 0 $0 4,000 $37,359 0 $0
2008-10 0 $0 2,000 $17,860 0 $0
2008-09 0 $0 1,289 $14,823 11,345 $0
2008-08 0 $0 5,500 $56,055 0 $0
2008-07 0 $0 13,766 $128,384 12,500 $72,625
2008-06 0 $0 839 $6,653 11,346 $0
2008-04 0 $0 15,388 $145,213 12,500 $72,625
2008-03 0 $0 3,213 $23,519 11,345 $0
2008-02 0 $0 0 $0 50,001 $455,370
2008-01 0 $0 26,245 $230,808 10,837 $92,500
2007-12 0 $0 51,470 $492,714 33,845 $169,919
2007-11 0 $0 2,497 $25,444 0 $0
2007-09 0 $0 0 $0 11,346 $0
2007-08 0 $0 10,000 $100,900 10,000 $90,000
2007-06 0 $0 0 $0 11,345 $0
2007-03 0 $0 0 $0 36,345 $222,500
2007-02 0 $0 0 $0 5,292 $37,500
2007-01 0 $0 7,000 $97,510 81,469 $0
2006-12 0 $0 4,800 $63,240 52,169 $0
2006-08 0 $0 0 $0 26,800 $235,750
2006-05 0 $0 0 $0 25,500 $110,000
2006-03 0 $0 8,000 $196,240 8,000 $20,000
2006-01 0 $0 0 $0 766 $0
2005-03 3,000 $61,080 0 $0 0 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Cv Therapeutics Inc insiders (CVTX)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2009-04-08 Stuart Lewis J (SVP COMMERCIAL OPERATIONS) Option Ex 117,058 12.39 1,449,880
2009-04-07 Shenk Thomas E (Director) Option Ex 35,000 13.68 478,625
2009-04-07 Gutshall Thomas L (Director) Option Ex 50,000 14.11 705,300
2009-04-06 Costa Santo J (Director) Option Ex 50,000 14.11 705,300
2009-04-03 Lee Kenneth B Jr (Director) Option Ex 56,250 14.11 793,462
2009-04-02 Suvari Tricia Borga (SVP, General Counsel & Sec) Option Ex 163,958 12.31 2,018,814
2009-04-02 Spiegelman Daniel K (SVP, CFO) Sale 141,029 19.91 2,807,887
2009-04-02 Spiegelman Daniel K (SVP, CFO) Option Ex 188,958 12.31 2,326,639
2009-04-02 Blackburn Brent K (SVP, Drug Discovery & Dev) Option Ex 213,958 13.49 2,886,721
2009-04-02 Lange Louis G (Chairman & CEO) Sale 479,175 19.90 9,535,582
2009-04-02 Lange Louis G (Chairman & CEO) Option Ex 641,083 15.14 9,702,791
2009-04-02 Davie Joseph Md Phd (Director) Option Ex 27,500 11.60 318,890
2009-03-25 Lange Louis G (Chairman & CEO) Option Ex 11,345 19.88 225,538
2009-02-25 Suvari Tricia Borga (SVP, General Counsel & Sec) Option Ex 12,499 15.58 194,734
2009-02-25 Spiegelman Daniel K (SVP, CFO) Option Ex 12,499 15.58 194,734
2009-02-25 Blackburn Brent K (SVP, Drug Discovery & Dev) Option Ex 12,499 15.58 194,734
2009-02-25 Lange Louis G (Chairman & CEO) Option Ex 50,000 15.58 779,000
2009-02-06 Blackburn Brent K (SVP, Drug Discovery & Dev) Sale 1,500 15.50 23,250
2009-01-15 Lange Louis G (Chairman & CEO) Option Ex 801 9.33 7,473
2009-01-07 Blackburn Brent K (SVP, Drug Discovery & Dev) Sale 1,500 9.38 14,070
2008-12-22 Lange Louis G (Chairman & CEO) Option Ex 11,346 8.91 101,092
2008-12-11 Stuart Lewis J (SVP COMMERCIAL OPERATIONS) Option Ex 2,700 8.48 22,896
2008-12-11 Suvari Tricia Borga (SVP, General Counsel & Sec) Option Ex 5,000 8.48 42,400
2008-12-11 Spiegelman Daniel K (SVP, CFO) Option Ex 5,000 8.48 42,400
2008-12-11 Blackburn Brent K (SVP, Drug Discovery & Dev) Option Ex 5,000 8.48 42,400
2008-12-11 Lange Louis G (Chairman & CEO) Option Ex 12,000 8.48 101,760
2008-12-10 Stuart Lewis J (SVP COMMERCIAL OPERATIONS) Sale 1,002 9.23 9,248
2008-12-09 Stuart Lewis J (SVP COMMERCIAL OPERATIONS) Option Ex 2,700 9.51 25,677
2008-12-09 Suvari Tricia Borga (SVP, General Counsel & Sec) Option Ex 5,000 9.51 47,550
2008-12-09 Spiegelman Daniel K (SVP, CFO) Option Ex 5,000 9.51 47,550
2008-12-09 Blackburn Brent K (SVP, Drug Discovery & Dev) Option Ex 5,000 9.51 47,550
2008-12-09 Lange Louis G (Chairman & CEO) Option Ex 12,000 9.51 114,120
2008-11-20 Stuart Lewis J (SVP COMMERCIAL OPERATIONS) Sale 2,000 8.19 16,379
2008-11-06 Blackburn Brent K (SVP, Drug Discovery & Dev) Sale 2,000 10.49 20,980
2008-10-14 Blackburn Brent K (SVP, Drug Discovery & Dev) Sale 2,000 8.93 17,860
2008-09-22 Lange Louis G (Chairman & CEO) Option Ex 11,345 .00 0
2008-09-09 Blackburn Brent K (SVP, Drug Discovery & Dev) Sale 1,289 11.50 14,823
2008-08-13 Blackburn Brent K (SVP, Drug Discovery & Dev) Sale 1,500 10.17 15,255
2008-08-08 Stuart Lewis J (SVP COMMERCIAL OPERATIONS) Sale 4,000 10.20 40,800
2008-07-31 Blackburn Brent K (SVP, Drug Discovery & Dev) Sale 12,500 9.50 118,750
2008-07-31 Blackburn Brent K (SVP, Drug Discovery & Dev) Option Ex 12,500 5.81 72,625
2008-07-08 Blackburn Brent K (SVP, Drug Discovery & Dev) Sale 1,266 7.61 9,634
2008-06-23 Lange Louis G (Chairman & CEO) Option Ex 11,346 .00 0
2008-06-17 Blackburn Brent K (SVP, Drug Discovery & Dev) Sale 839 7.93 6,653
2008-04-30 Suvari Tricia Borga (SVP, General Counsel & Sec) Sale 2,888 9.12 26,338
2008-04-25 Blackburn Brent K (SVP, Drug Discovery & Dev) Sale 12,500 9.51 118,875
2008-04-25 Blackburn Brent K (SVP, Drug Discovery & Dev) Option Ex 12,500 5.81 72,625
2008-03-31 Suvari Tricia Borga (SVP, General Counsel & Sec) Sale 3,213 7.32 23,519
2008-03-24 Lange Louis G (Chairman & CEO) Option Ex 11,345 .00 0
2008-02-26 Stuart Lewis J (SVP COMMERCIAL OPERATIONS) Option Ex 4,688 6.95 32,581
2008-02-26 Suvari Tricia Borga (SVP, General Counsel & Sec) Option Ex 4,688 6.95 32,581
2008-02-26 Spiegelman Daniel K (SVP, CFO) Option Ex 4,688 6.95 32,581
2008-02-26 Blackburn Brent K (SVP, Drug Discovery & Dev) Option Ex 4,688 6.95 32,581
2008-02-26 Lange Louis G (Chairman & CEO) Option Ex 18,750 6.95 130,312
2008-02-25 Stuart Lewis J (SVP COMMERCIAL OPERATIONS) Option Ex 12,499 15.58 194,734
2008-01-31 Suvari Tricia Borga (SVP, General Counsel & Sec) Sale 16,245 8.36 135,808
2008-01-10 Blackburn Brent K (SVP, Drug Discovery & Dev) Sale 10,000 9.50 95,000
2008-01-10 Blackburn Brent K (SVP, Drug Discovery & Dev) Option Ex 10,000 9.25 92,500
2008-01-10 Lange Louis G (Chairman & CEO) Option Ex 837 .00 0
2007-12-24 Lange Louis G (Chairman & CEO) Option Ex 11,345 .00 0
2007-12-21 Spiegelman Daniel K (SVP, CFO) Sale 6,000 10.00 60,000
2007-12-19 Suvari Tricia Borga (SVP, General Counsel & Sec) Sale 11,019 9.20 101,374
2007-12-18 Gutshall Thomas L (Director) Sale 7,500 9.01 67,560
2007-12-18 Gutshall Thomas L (Director) Option Ex 7,500 4.16 31,169
2007-12-11 Blackburn Brent K (SVP, Drug Discovery & Dev) Sale 18,951 9.68 183,540
2007-12-11 Blackburn Brent K (SVP, Drug Discovery & Dev) Option Ex 15,000 9.25 138,750
2007-12-10 Spiegelman Daniel K (SVP, CFO) Sale 8,000 10.03 80,240
2007-11-09 Stuart Lewis J (SVP COMMERCIAL OPERATIONS) Sale 2,497 10.19 25,444
2007-09-24 Lange Louis G (Chairman & CEO) Option Ex 11,346 .00 0
2007-08-16 Blackburn Brent K (SVP, Drug Discovery & Dev) Sale 10,000 10.09 100,900
2007-08-16 Blackburn Brent K (SVP, Drug Discovery & Dev) Option Ex 10,000 9.00 90,000
2007-06-22 Lange Louis G (Chairman & CEO) Option Ex 11,345 .00 0
2007-03-30 Mcneil Barbara J (Director) Option Ex 5,000 7.50 37,500
2007-03-22 Lange Louis G (Chairman & CEO) Option Ex 11,345 .00 0
2007-03-08 Lange Louis G (Chairman & CEO) Option Ex 20,000 9.25 185,000
2007-02-22 Lange Louis G (Chairman & CEO) Option Ex 292 .00 0
2007-02-21 Gutshall Thomas L (Director) Option Ex 5,000 7.50 37,500
2007-01-17 Spiegelman Daniel K (SVP, CFO) Sale 7,000 13.93 97,510
2007-01-03 Mccaleb David C (SVP Commercial Operations) Option Ex 12,732 .00 0
2007-01-03 Suvari Tricia Borga (SVP, Gen Counsel, Asst Sec) Option Ex 12,732 .00 0
2007-01-03 Spiegelman Daniel K (SVP, CFO) Option Ex 12,732 .00 0
2007-01-03 Blackburn Brent K (SVP, Drug Discovery & Dev) Option Ex 12,732 .00 0
2007-01-03 Lange Louis G (Chairman & CEO) Option Ex 30,541 .00 0
2006-12-22 Lange Louis G (Chairman & CEO) Option Ex 20,169 .00 0
2006-12-19 Mcneil Barbara J (Director) Sale 1,800 13.60 24,480
2006-12-12 Spiegelman Daniel K (SVP, CFO) Sale 3,000 12.92 38,760
2006-12-05 Mccaleb David C (SVP Commercial Operations) Option Ex 5,000 .00 0
2006-12-05 Suvari Tricia Borga (SVP, Gen Counsel, Asst Sec) Option Ex 5,000 .00 0
2006-12-05 Spiegelman Daniel K (SVP, CFO) Option Ex 5,000 .00 0
2006-12-05 Blackburn Brent K (SVP, Drug Discovery & Dev) Option Ex 5,000 .00 0
2006-12-05 Lange Louis G (Chairman & CEO) Option Ex 12,000 .00 0
2006-08-23 Mcneil Barbara J (Director) Option Ex 1,800 2.50 4,500
2006-08-23 Lange Louis G (Chairman & CEO) Option Ex 25,000 9.25 231,250
2006-05-17 Mccaleb David C (SVP Commercial Operations) Option Ex 10,000 7.12 71,250
2006-05-09 Gutshall Thomas L (Director) Option Ex 15,500 2.50 38,750
2006-03-07 Mcneil Barbara J (Director) Sale 8,000 24.53 196,240
2006-03-07 Mcneil Barbara J (Director) Option Ex 8,000 2.50 20,000
2006-01-03 Mccaleb David C (SVP Commercial Opera) Option Ex 121 .00 0
2006-01-03 Suvari Tricia Borga (VP, Gen Counsel, Ass) Option Ex 121 .00 0
2006-01-03 Spiegelman Daniel K (SVP, CFO) Option Ex 121 .00 0
2006-01-03 Blackburn Brent K (SVP, Drug Discovery) Option Ex 121 .00 0
2006-01-03 Lange Louis G (Chairman & CEO) Option Ex 282 .00 0
2005-03-14 Shenk Thomas E (Director) Buy 2,000 20.36 40,720

Insider trading activities including stock purchases, stock sales, and option exercises of CVTX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Cv Therapeutics Inc (symbol CVTX, CIK number 921506) see the Securities and Exchange Commission (SEC) website.